Scholarlink

Purpose <p>Patients with nasopharyngeal carcinoma (NPC) exhibiting persistent EBV DNA positivity throughout treatment (a “D-D-D” trajectory) represent a high-risk group with undefined management strategies. This study aimed to define critical post-radiotherapy timepoints to establish a precision surveillance strategy for these patients.</p> Methods <p>In a longitudinal cohort of non-metastatic “D-D-D” NPC patients, plasma Epstein-Barr virus (EBV) DNA was quantified at 1.5, 3, 6, 9, and 12 months post-radiotherapy. A time-dependent Cox model was employed to evaluate the dynamic prognostic value of EBV DNA status. Model performance was rigorously compared using Harrell’s C-index, the Akaike information criterion, and net reclassification improvement. Classification metrics, including sensitivity, specificity, and predictive values, were analyzed to identify clinically actionable decision points.</p> Results <p>Among 295 patients, early clearance by 1.5 months (10.5% of the cohort) conferred favorable survival, comparable to the “D-D-U” subgroup from our previous analysis. The 12-month EBV DNA status emerged as the strongest independent predictor of disease progression (adjusted HR = 2.804, 95% CI: 2.273–3.460, <i>P</i> &lt; 0.001), offering high specificity (98.6%) but delayed intervention. In contrast, the 1.5-month timepoint, while highly sensitive (95.0%), generated an unactionable alert rate (89.0%). The 3-month assessment optimally balanced these parameters, maintaining substantial sensitivity (76.7%) within a clinically actionable alert rate (65.5%).</p> Conclusions <p>We propose a time-adapted risk stratification framework wherein the 3-month assessment identifies patients for intensified surveillance, while persistent EBV DNA at 12 months identifies a population at high risk of progression. The clinical benefit of timepoint-guided interventions warrants prospective randomized investigation.</p> Clinical trial number <p>Not applicable</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A time-adapted risk stratification framework guided by longitudinal post-radiotherapy EBV DNA clearance for high-risk nasopharyngeal carcinoma patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月26日

查看全文
  • Ying Li,
  • Zongwei Huang,
  • Zihan Chen,
  • Mingzhu Liu,
  • Jue Wang,
  • Jiajia Zheng,
  • Qisi Zhang,
  • Xiaoke Wang,
  • Yuhui Pan,
  • Sufang Qiu

摘要

Purpose

Patients with nasopharyngeal carcinoma (NPC) exhibiting persistent EBV DNA positivity throughout treatment (a “D-D-D” trajectory) represent a high-risk group with undefined management strategies. This study aimed to define critical post-radiotherapy timepoints to establish a precision surveillance strategy for these patients.

Methods

In a longitudinal cohort of non-metastatic “D-D-D” NPC patients, plasma Epstein-Barr virus (EBV) DNA was quantified at 1.5, 3, 6, 9, and 12 months post-radiotherapy. A time-dependent Cox model was employed to evaluate the dynamic prognostic value of EBV DNA status. Model performance was rigorously compared using Harrell’s C-index, the Akaike information criterion, and net reclassification improvement. Classification metrics, including sensitivity, specificity, and predictive values, were analyzed to identify clinically actionable decision points.

Results

Among 295 patients, early clearance by 1.5 months (10.5% of the cohort) conferred favorable survival, comparable to the “D-D-U” subgroup from our previous analysis. The 12-month EBV DNA status emerged as the strongest independent predictor of disease progression (adjusted HR = 2.804, 95% CI: 2.273–3.460, P < 0.001), offering high specificity (98.6%) but delayed intervention. In contrast, the 1.5-month timepoint, while highly sensitive (95.0%), generated an unactionable alert rate (89.0%). The 3-month assessment optimally balanced these parameters, maintaining substantial sensitivity (76.7%) within a clinically actionable alert rate (65.5%).

Conclusions

We propose a time-adapted risk stratification framework wherein the 3-month assessment identifies patients for intensified surveillance, while persistent EBV DNA at 12 months identifies a population at high risk of progression. The clinical benefit of timepoint-guided interventions warrants prospective randomized investigation.

Clinical trial number

Not applicable